{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:59:54Z","timestamp":1794502794597,"version":"4.9.1"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Chem"],"DOI":"10.1038\/s41570-025-00763-x","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:21:52Z","timestamp":1759926112000},"page":"790-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The impact of chemical reactivity on the quality and stability of RNA\u2013LNP pharmaceuticals\u00a0\u00a0"],"prefix":"10.1038","volume":"9","author":[{"given":"Tristan","family":"Kova\u010di\u010d","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5517-5970","authenticated-orcid":false,"given":"Heinrich","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Stotsky-Oterin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"\u0160trancar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8806-3019","authenticated-orcid":false,"given":"Urban","family":"Bren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8238-0673","authenticated-orcid":false,"given":"Dan","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"763_CR1","volume":"10","author":"GS Naidu","year":"2023","unstructured":"Naidu, G. S. et al. A combinatorial library of lipid nanoparticles for cell type-specific mRNA delivery. Adv. Sci. 10, 2301929 (2023).","journal-title":"Adv. Sci."},{"key":"763_CR2","volume":"32","author":"S Ramishetti","year":"2020","unstructured":"Ramishetti, S. et al. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes. Adv. Mater. 32, 1906128 (2020).","journal-title":"Adv. Mater."},{"key":"763_CR3","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115175","volume":"205","author":"P Sharma","year":"2024","unstructured":"Sharma, P., Hoorn, D., Aitha, A., Breier, D. & Peer, D. The immunostimulatory nature of mRNA lipid nanoparticles. Adv. Drug Deliv. Rev. 205, 115175 (2024).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"763_CR4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709\u2013722 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"763_CR5","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","volume":"86","author":"RW Malone","year":"1989","unstructured":"Malone, R. W., Felgner, P. L. & Verma, I. M. Cationic liposome-mediated RNA transfection. Proc. Natl Acad. Sci. USA 86, 6077\u20136081 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"763_CR6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i4.10","volume":"21","author":"D Simberg","year":"2004","unstructured":"Simberg, D., Weisman, S., Talmon, Y. & Barenholz, Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit. Rev. Ther. Drug Carr. Syst. 21, 257\u2013317 (2004).","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"763_CR7","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.biomaterials.2010.05.027","volume":"31","author":"R Kedmi","year":"2010","unstructured":"Kedmi, R., Ben-Arie, N. & Peer, D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31, 6867\u20136875 (2010).","journal-title":"Biomaterials"},{"key":"763_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"763_CR9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"763_CR10","volume":"8","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ Vaccines 8, 156 (2023).","journal-title":"NPJ Vaccines"},{"key":"763_CR11","unstructured":"US Pharmacopeia. USP mRNA vaccine chapter (USP, 2023)."},{"key":"763_CR12","unstructured":"Qiu, X. Introduction to the technical requirements in the guidelines on prophylactic COVID-19 mRNA vaccines. in CMC Strategy Forum China (CMC, 2022)."},{"key":"763_CR13","volume":"16","author":"SK Niazi","year":"2024","unstructured":"Niazi, S. K. The United States Food and Drug Administration\u2019s platform technology designation to expedite the development of drugs. Pharmaceutics 16, 918 (2024).","journal-title":"Pharmaceutics"},{"key":"763_CR14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/jps.2600840915","volume":"84","author":"NJ Zuidam","year":"1995","unstructured":"Zuidam, N. J. & Crommelin, D. J. A. Chemical hydrolysis of phospholipids. J. Pharm. Sci. 84, 1113\u20131119 (1995).","journal-title":"J. Pharm. Sci."},{"key":"763_CR15","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1021\/ac404214a","volume":"86","author":"Y Zhou","year":"2014","unstructured":"Zhou, Y., Park, H., Kim, P., Jiang, Y. & Costello, C. E. Surface oxidation under ambient air \u2014 not only a fast and economical method to identify double bond positions in unsaturated lipids but also a reminder of proper lipid processing. Anal. Chem. 86, 5697\u20135705 (2014).","journal-title":"Anal. Chem."},{"key":"763_CR16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0165-1218(78)90012-5","volume":"58","author":"DR Wade","year":"1978","unstructured":"Wade, D. R., Airy, S. C. & Sinsheimer, J. E. Mutagenicity of aliphatic epoxides. Mutat. Res. Genet. Toxicol. 58, 217\u2013223 (1978).","journal-title":"Mutat. Res. Genet. Toxicol."},{"key":"763_CR17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","volume":"20","author":"E Kon","year":"2023","unstructured":"Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L. & Peer, D. Targeting cancer with mRNA\u2013lipid nanoparticles: key considerations and future prospects. Nat. Rev. Clin. Oncol. 20, 739\u2013754 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"763_CR18","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102520","volume":"36","author":"B Dietmair","year":"2025","unstructured":"Dietmair, B. et al. Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell surface markers. Mol. Ther. Nucleic Acids 36, 102520 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"763_CR19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jconrel.2024.10.014","volume":"376","author":"D Tarab-Ravski","year":"2024","unstructured":"Tarab-Ravski, D. et al. The future of genetic medicines delivered via targeted lipid nanoparticles to leukocytes. J. Control. Rel. 376, 286\u2013302 (2024).","journal-title":"J. Control. Rel."},{"key":"763_CR20","volume":"9","author":"D Rosenblum","year":"2018","unstructured":"Rosenblum, D., Joshi, N., Tao, W., Karp, J. M. & Peer, D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun. 9, 1410 (2018).","journal-title":"Nat. Commun."},{"key":"763_CR21","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14112357","volume":"14","author":"M Kamiya","year":"2022","unstructured":"Kamiya, M. et al. Stability study of mRNA-lipid nanoparticles exposed to various conditions based on the evaluation between physicochemical properties and their relation with protein expression ability. Pharmaceutics 14, 2357 (2022).","journal-title":"Pharmaceutics"},{"key":"763_CR22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/acs.molpharmaceut.7b01022","volume":"15","author":"A Ziller","year":"2018","unstructured":"Ziller, A. et al. Incorporation of mRNA in lamellar lipid matrices for parenteral administration. Mol. Pharm. 15, 642\u2013651 (2018).","journal-title":"Mol. Pharm."},{"key":"763_CR23","unstructured":"Haas, H., Hernan, I. & Borquez, E. Stable formulations of lipids and liposomes. International patent WO2016046060A1 (2016)."},{"key":"763_CR24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26926-0","volume":"12","author":"M Packer","year":"2021","unstructured":"Packer, M., Gyawali, D., Yerabolu, R., Schariter, J. & White, P. A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems. Nat. Commun. 12, 6777 (2021).","journal-title":"Nat. Commun."},{"key":"763_CR25","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1021\/acs.analchem.3c04406","volume":"96","author":"MS Lowenthal","year":"2024","unstructured":"Lowenthal, M. S., Antonishek, A. S. & Phinney, K. W. Quantification of mRNA in lipid nanoparticles using mass spectrometry. Anal. Chem. 96, 1214\u20131222 (2024).","journal-title":"Anal. Chem."},{"key":"763_CR26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115174","volume":"224","author":"S Fekete","year":"2023","unstructured":"Fekete, S. et al. Challenges and emerging trends in liquid chromatography-based analyses of mRNA pharmaceuticals. J. Pharm. Biomed. Anal. 224, 115174 (2023).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"763_CR27","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-024-06235-0","volume":"7","author":"K Hashiba","year":"2024","unstructured":"Hashiba, K. et al. Overcoming thermostability challenges in mRNA\u2013lipid nanoparticle systems with piperidine-based ionizable lipids. Commun. Biol. 7, 556 (2024).","journal-title":"Commun. Biol."},{"key":"763_CR28","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202200906","volume":"28","author":"F Saadati","year":"2022","unstructured":"Saadati, F., Cammarone, S. & Ciufolini, M. A. A route to lipid ALC-0315: a key component of a COVID-19 mRNA vaccine. Chem. Eur. J. 28, e202200906 (2022).","journal-title":"Chem. Eur. J."},{"key":"763_CR29","doi-asserted-by":"crossref","DOI":"10.1002\/smsc.202300285","volume":"3","author":"K Hashiba","year":"2023","unstructured":"Hashiba, K. et al. Branching ionizable lipids can enhance the stability, fusogenicity, and functional delivery of mRNA. Small Sci. 3, 2200071 (2023).","journal-title":"Small Sci."},{"key":"763_CR30","doi-asserted-by":"publisher","unstructured":"Han, X. et al. Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo. Nat. Chem. https:\/\/doi.org\/10.1038\/s41557-024-01557-2 (2024).","DOI":"10.1038\/s41557-024-01557-2"},{"key":"763_CR31","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2023.464545","volume":"1714","author":"C Malburet","year":"2024","unstructured":"Malburet, C., Carboni, A., Guinamand, S., Naik, H. & Fertier-Prizzon, S. mRNA extraction from lipid nanoparticles. J. Chromatogr. A 1714, 464545 (2024).","journal-title":"J. Chromatogr. A"},{"key":"763_CR32","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2015.00476","volume":"6","author":"MA Lever","year":"2015","unstructured":"Lever, M. A. et al. A modular method for the extraction of DNA and RNA, and the separation of DNA pools from diverse environmental sample types. Front. Microbiol. 6, 476 (2015).","journal-title":"Front. Microbiol."},{"key":"763_CR33","doi-asserted-by":"crossref","first-page":"22989","DOI":"10.1021\/acsnano.4c04519","volume":"18","author":"N Aliakbarinodehi","year":"2024","unstructured":"Aliakbarinodehi, N. et al. Time-resolved inspection of ionizable lipid-facilitated lipid nanoparticle disintegration and cargo release at an early endosomal membrane mimic. ACS Nano 18, 22989\u201323000 (2024).","journal-title":"ACS Nano"},{"key":"763_CR34","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-021-02441-2","volume":"4","author":"MJ Carrasco","year":"2021","unstructured":"Carrasco, M. J. et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun. Biol. 4, 956 (2021).","journal-title":"Commun. Biol."},{"key":"763_CR35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","volume":"73","author":"E Kon","year":"2022","unstructured":"Kon, E., Elia, U. & Peer, D. Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr. Opin. Biotechnol. 73, 329\u2013336 (2022).","journal-title":"Curr. Opin. Biotechnol."},{"key":"763_CR36","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2311700120","volume":"121","author":"G Tesei","year":"2024","unstructured":"Tesei, G. et al. Lipid shape and packing are key for optimal design of pH-sensitive mRNA lipid nanoparticles. Proc. Natl Acad. Sci. USA 121, e2311700120 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"763_CR37","doi-asserted-by":"crossref","DOI":"10.1002\/marc.202100683","volume":"43","author":"G Settanni","year":"2022","unstructured":"Settanni, G., Brill, W., Haas, H. & Schmid, F. pH-dependent behavior of ionizable cationic lipids in mRNA-carrying lipoplexes investigated by molecular dynamics simulations. Macromol. Rapid Commun. 43, 2270035 (2022).","journal-title":"Macromol. Rapid Commun."},{"key":"763_CR38","doi-asserted-by":"crossref","first-page":"13331","DOI":"10.1021\/acs.langmuir.0c02446","volume":"36","author":"L Uebbing","year":"2020","unstructured":"Uebbing, L. et al. Investigation of pH-responsiveness inside lipid nanoparticles for parenteral mRNA application using small-angle X-ray scattering. Langmuir 36, 13331\u201313341 (2020).","journal-title":"Langmuir"},{"key":"763_CR39","doi-asserted-by":"publisher","unstructured":"Wilhelmy, C. et al. Direct structural investigation of pH responsiveness in mRNA lipid nanoparticles: refining paradigms. J. Control. Rel. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113848 (2025).","DOI":"10.1016\/j.jconrel.2025.113848"},{"key":"763_CR40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114380","volume":"201","author":"D Schlattmann","year":"2024","unstructured":"Schlattmann, D., Weber, B., Wyszynski, L., Sch\u00f6nhoff, M. & Haas, H. Molecular localization and exchange kinetics in pharmaceutical liposome and mRNA lipoplex nanoparticle products determined by small angle X-ray scattering and pulsed field gradient NMR diffusion measurements. Eur. J. Pharm. Biopharm. 201, 114380 (2024).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"763_CR41","first-page":"E3351","volume":"115","author":"MY Arteta","year":"2018","unstructured":"Arteta, M. Y. et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc. Natl Acad. Sci. USA 115, E3351\u2013E3360 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"763_CR42","volume":"10","author":"A Ouranidis","year":"2022","unstructured":"Ouranidis, A. et al. mRNA therapeutic modalities design, formulation and manufacturing under Pharma 4.0 principles. Biomedicines 10, 50 (2022).","journal-title":"Biomedicines"},{"key":"763_CR43","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121570","volume":"286","author":"M Ripoll","year":"2022","unstructured":"Ripoll, M. et al. An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates. Biomaterials 286, 121570 (2022).","journal-title":"Biomaterials"},{"key":"763_CR44","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1021\/acsnano.2c11904","volume":"17","author":"J Szebeni","year":"2023","unstructured":"Szebeni, J. et al. Insights into the structure of Comirnaty Covid-19 vaccine: a theory on soft, partially bilayer-covered nanoparticles with hydrogen bond-stabilized mRNA\u2013lipid complexes. ACS Nano 17, 13147\u201313157 (2023).","journal-title":"ACS Nano"},{"key":"763_CR45","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202106727","volume":"32","author":"M Cornebise","year":"2022","unstructured":"Cornebise, M. et al. Discovery of a novel amino lipid that improves lipid nanoparticle performance through specific interactions with mRNA. Adv. Funct. Mater. 32, 2106727 (2022).","journal-title":"Adv. Funct. Mater."},{"key":"763_CR46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<443::AID-JPS2>3.0.CO;2-W","volume":"89","author":"D Pogocki","year":"2000","unstructured":"Pogocki, D. & Sch\u00f6neich, C. Chemical stability of nucleic acid\u2013derived drugs. J. Pharm. Sci. 89, 443\u2013456 (2000).","journal-title":"J. Pharm. Sci."},{"key":"763_CR47","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1021\/jo961935u","volume":"62","author":"M Komiyama","year":"1997","unstructured":"Komiyama, M. & Yoshinari, K. Kinetic analysis of diamine-catalyzed RNA hydrolysis. J. Org. Chem. 62, 2155\u20132160 (1997).","journal-title":"J. Org. Chem."},{"key":"763_CR48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.xphs.2023.11.023","volume":"113","author":"U Chheda","year":"2024","unstructured":"Chheda, U. et al. Factors affecting stability of RNA \u2014 temperature, length, concentration, pH, and buffering species. J. Pharm. Sci. 113, 377\u2013385 (2024).","journal-title":"J. Pharm. Sci."},{"key":"763_CR49","volume":"14","author":"Z Kis","year":"2022","unstructured":"Kis, Z. Stability modelling of mRNA vaccine quality based on temperature monitoring throughout the distribution chain. Pharmaceutics 14, 430 (2022).","journal-title":"Pharmaceutics"},{"key":"763_CR50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2022.106780","volume":"285","author":"MK Franco","year":"2022","unstructured":"Franco, M. K. & Koutmou, K. S. Chemical modifications to mRNA nucleobases impact translation elongation and termination. Biophys. Chem. 285, 106780 (2022).","journal-title":"Biophys. Chem."},{"key":"763_CR51","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1093\/nar\/gkf540","volume":"30","author":"S Lemieux","year":"2002","unstructured":"Lemieux, S. & Major, F. RNA canonical and non-canonical base pairing types: a recognition method and complete repertoire. Nucleic Acids Res. 30, 4250\u20134263 (2002).","journal-title":"Nucleic Acids Res."},{"key":"763_CR52","unstructured":"Monroe, J. G., Smith, T. J. & Koutmou, K. S. in Methods in Enzymology Vol. 658 (ed. Jackman, J. E.) Ch. 16, 379\u2013406 (Academic, 2021)."},{"key":"763_CR53","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1021\/acs.molpharmaceut.2c00092","volume":"19","author":"M Kloczewiak","year":"2022","unstructured":"Kloczewiak, M., Banks, J. M., Jin, L. & Brader, M. L. A biopharmaceutical perspective on higher-order structure and thermal stability of mRNA vaccines. Mol. Pharm. 19, 2022\u20132031 (2022).","journal-title":"Mol. Pharm."},{"key":"763_CR54","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202206968","volume":"19","author":"AM J\u00f6rgensen","year":"2023","unstructured":"J\u00f6rgensen, A. M., Wibel, R. & Bernkop-Schn\u00fcrch, A. Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients. Small 19, 2206968 (2023).","journal-title":"Small"},{"key":"763_CR55","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1021\/acs.analchem.3c05539","volume":"96","author":"J Camperi","year":"2024","unstructured":"Camperi, J. et al. Comprehensive impurity profiling of mRNA: evaluating current technologies and advanced analytical techniques. Anal. Chem. 96, 3886\u20133897 (2024).","journal-title":"Anal. Chem."},{"key":"763_CR56","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D Bitounis","year":"2024","unstructured":"Bitounis, D., Jacquinet, E., Rogers, M. A. & Amiji, M. M. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat. Rev. Drug Discov. 23, 281\u2013300 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"763_CR57","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/mt.2015.222","volume":"24","author":"Y Sato","year":"2016","unstructured":"Sato, Y., Hatakeyama, H., Hyodo, M. & Harashima, H. Relationship between the physicochemical properties of lipid nanoparticles and the quality of siRNA delivery to liver cells. Mol. Ther. 24, 788\u2013795 (2016).","journal-title":"Mol. Ther."},{"key":"763_CR58","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1021\/acs.bioconjchem.0c00366","volume":"31","author":"V Francia","year":"2020","unstructured":"Francia, V., Schiffelers, R. M., Cullis, P. R. & Witzigmann, D. The biomolecular corona of lipid nanoparticles for gene therapy. Bioconjug. Chem. 31, 2046\u20132059 (2020).","journal-title":"Bioconjug. Chem."},{"key":"763_CR59","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mrc.5516","volume":"63","author":"G Khirich","year":"2025","unstructured":"Khirich, G. et al. Quantification of mRNA using 31P NMR spectroscopy and CRAFT. Magn. Reson. Chem. 63, 370\u2013379 (2025).","journal-title":"Magn. Reson. Chem."},{"key":"763_CR60","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2024.103156","volume":"327","author":"L Caselli","year":"2024","unstructured":"Caselli, L., Conti, L., De Santis, I. & Berti, D. Small-angle X-ray and neutron scattering applied to lipid-based nanoparticles: recent advancements across different length scales. Adv. Colloid Interface Sci. 327, 103156 (2024).","journal-title":"Adv. Colloid Interface Sci."},{"key":"763_CR61","doi-asserted-by":"crossref","DOI":"10.3390\/cells9092034","volume":"9","author":"CD Siewert","year":"2020","unstructured":"Siewert, C. D. et al. Hybrid biopolymer and lipid nanoparticles with improved transfection efficacy for mRNA. Cells 9, 2034 (2020).","journal-title":"Cells"},{"key":"763_CR62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114235","volume":"198","author":"SS Nogueira","year":"2024","unstructured":"Nogueira, S. S. et al. Analytical techniques for the characterization of nanoparticles for mRNA delivery. Eur. J. Pharm. Biopharm. 198, 114235 (2024).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"763_CR63","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/elps.202100244","volume":"43","author":"C Kinsey","year":"2022","unstructured":"Kinsey, C. et al. Determination of lipid content and stability in lipid nanoparticles using ultra high-performance liquid chromatography in combination with a corona charged aerosol detector. Electrophoresis 43, 1091\u20131100 (2022).","journal-title":"Electrophoresis"},{"key":"763_CR64","volume":"1709","author":"KH Kim","year":"2023","unstructured":"Kim, K. H. et al. Optimization of HPLCCAD method for simultaneous analysis of different lipids in lipid nanoparticles with analytical QbD. J. Chromatogr. A 1709, 464375 (2023).","journal-title":"J. Chromatogr. A"},{"key":"763_CR65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2024.124005","volume":"1234","author":"RE Birdsall","year":"2024","unstructured":"Birdsall, R. E. et al. Monitoring stability indicating impurities and aldehyde content in lipid nanoparticle raw material and formulated drugs. J. Chromatogr. B 1234, 124005 (2024).","journal-title":"J. Chromatogr. B"},{"key":"763_CR66","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.18609\/cgti.2023.161","volume":"09","author":"A Budihna","year":"2023","unstructured":"Budihna, A., Martincic Celjar, A., Lebar, S., Livk, A. & Strancar, A. mRNA fragmentation and quality assessment using ion pair reverse-phase analytics. Cell Gene Ther. Insights 09, 1231\u20131247 (2023).","journal-title":"Cell Gene Ther. Insights"},{"key":"763_CR67","unstructured":"Toppazzini, M. et al. Analytical method. International patent WO2024171052A1 (2024)."},{"key":"763_CR68","unstructured":"Gagnon, P. Purification of Nucleic Acids: A Handbook for Purification of DNA Plasmids and MRNA for Gene Therapy and Vaccines (BIA Separations, 2020)."},{"key":"763_CR69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116144","volume":"245","author":"J Currie","year":"2024","unstructured":"Currie, J. et al. Stability indicating ion-pair reversed-phase liquid chromatography method for modified mRNA. J. Pharm. Biomed. Anal. 245, 116144 (2024).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"763_CR70","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbagrm.2018.10.012","volume":"1862","author":"M Jora","year":"2019","unstructured":"Jora, M., Lobue, P. A., Ross, R. L., Williams, B. & Addepalli, B. Detection of ribonucleoside modifications by liquid chromatography coupled with mass spectrometry. Biochim. Biophys. Acta Gene Regul. Mech. 1862, 280\u2013290 (2019).","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"763_CR71","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.tifs.2019.01.015","volume":"85","author":"V Cort\u00e9s","year":"2019","unstructured":"Cort\u00e9s, V., Blasco, J., Aleixos, N., Cubero, S. & Talens, P. Monitoring strategies for quality control of agricultural products using visible and near-infrared spectroscopy: a review. Trends Food Sci. Technol. 85, 138\u2013148 (2019).","journal-title":"Trends Food Sci. Technol."},{"key":"763_CR72","doi-asserted-by":"crossref","unstructured":"Geinguenaud, F., Militello, V. & Arluison, V. in RNA Spectroscopy: Methods and Protocols (eds Arluison, V. and Wien, F.) 119\u2013133 (Springer, 2020).","DOI":"10.1007\/978-1-0716-0278-2_10"},{"key":"763_CR73","doi-asserted-by":"crossref","DOI":"10.3390\/life14040436","volume":"14","author":"S Iglesias-Groth","year":"2024","unstructured":"Iglesias-Groth, S., Cataldo, F. & Marin-Dobrincic, M. Infrared spectroscopy of RNA nucleosides in a wide range of temperatures. Life 14, 436 (2024).","journal-title":"Life"},{"key":"763_CR74","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1039\/C3AN02329J","volume":"139","author":"W-P Peng","year":"2014","unstructured":"Peng, W.-P., Chou, S.-W. & Patil, A. A. Measuring masses of large biomolecules and bioparticles using mass spectrometric techniques. Analyst 139, 3507\u20133523 (2014).","journal-title":"Analyst"},{"key":"763_CR75","volume":"13","author":"BC Gau","year":"2023","unstructured":"Gau, B. C. et al. Oligonucleotide mapping via mass spectrometry to enable comprehensive primary structure characterization of an mRNA vaccine against SARS-CoV-2. Sci. Rep. 13, 9038 (2023).","journal-title":"Sci. Rep."},{"key":"763_CR76","doi-asserted-by":"crossref","first-page":"15017","DOI":"10.1021\/acs.analchem.3c02944","volume":"95","author":"A Goyon","year":"2023","unstructured":"Goyon, A. et al. Separation of plasmid DNA topological forms, messenger RNA, and lipid nanoparticle aggregates using an ultrawide pore size exclusion chromatography column. Anal. Chem. 95, 15017\u201315024 (2023).","journal-title":"Anal. Chem."},{"key":"763_CR77","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.464756","volume":"1719","author":"J De Vos","year":"2024","unstructured":"De Vos, J. et al. Evaluation of size-exclusion chromatography, multi-angle light scattering detection and mass photometry for the characterization of mRNA. J. Chromatogr. A 1719, 464756 (2024).","journal-title":"J. Chromatogr. A"},{"key":"763_CR78","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42274-z","volume":"13","author":"MA Graewert","year":"2023","unstructured":"Graewert, M. A. et al. Quantitative size-resolved characterization of mRNA nanoparticles by in-line coupling of asymmetrical-flow field-flow fractionation with small angle X-ray scattering. Sci. Rep. 13, 15764 (2023).","journal-title":"Sci. Rep."},{"key":"763_CR79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ymeth.2016.10.008","volume":"113","author":"WA Cantara","year":"2017","unstructured":"Cantara, W. A., Olson, E. D. & Musier-Forsyth, K. Analysis of RNA structure using small-angle X-ray scattering. Methods 113, 46\u201355 (2017).","journal-title":"Methods"},{"key":"763_CR80","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2217\/nnm-2022-0024","volume":"17","author":"BC Nelson","year":"2022","unstructured":"Nelson, B. C. & Borgos, S. E. High-throughput synthesis and characterization of next-generation lipid nanoparticles for enhanced in vivo performance. Nanomedicine 17, 573\u2013576 (2022).","journal-title":"Nanomedicine"},{"key":"763_CR81","unstructured":"Roberts, J. P. Improving the manufacture of mRNA biologics. Genetic Engineering and Biotechnology News https:\/\/www.genengnews.com\/topics\/bioprocessing\/improving-the-manufacture-of-mrna-biologics-2\/ (2024)."},{"key":"763_CR82","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1021\/acs.analchem.3c01761","volume":"96","author":"LM Almehmadi","year":"2024","unstructured":"Almehmadi, L. M., Reverdatto, S. V., Ermolenkov, V. V., Shekhtman, A. & Lednev, I. K. In situ stability test for mRNA vaccines based on deep-UV resonance Raman spectroscopy. Anal. Chem. 96, 1003\u20131008 (2024).","journal-title":"Anal. Chem."},{"key":"763_CR83","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06397-6","volume":"9","author":"J Penders","year":"2018","unstructured":"Penders, J. et al. Single particle automated Raman trapping analysis. Nat. Commun. 9, 4256 (2018).","journal-title":"Nat. Commun."},{"key":"763_CR84","volume":"34","author":"HMG Barriga","year":"2022","unstructured":"Barriga, H. M. G. et al. Coupling lipid nanoparticle structure and automated single-particle composition analysis to design phospholipase-responsive nanocarriers. Adv. Mater. 34, 2200839 (2022).","journal-title":"Adv. Mater."},{"key":"763_CR85","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2024.116457","volume":"261","author":"J Reitemeier","year":"2024","unstructured":"Reitemeier, J., Metro, J. & Bohn, P. W. Detection of aldehydes from degradation of lipid nanoparticle formulations using a hierarchically-organized nanopore electrochemical biosensor. Biosens. Bioelectron. 261, 116457 (2024).","journal-title":"Biosens. Bioelectron."},{"key":"763_CR86","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461767","volume":"1635","author":"F Caputo","year":"2021","unstructured":"Caputo, F. et al. Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals. The joint view of European Union Nanomedicine Characterization Laboratory and National Cancer Institute \u2014 Nanotechnology Characterization Laboratory. J. Chromatogr. A 1635, 461767 (2021).","journal-title":"J. Chromatogr. A"},{"key":"763_CR87","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00249-023-01663-y","volume":"52","author":"A Bepperling","year":"2023","unstructured":"Bepperling, A. & Richter, G. Determination of mRNA copy number in degradable lipid nanoparticles via density contrast analytical ultracentrifugation. Eur. Biophys. J. 52, 393\u2013400 (2023).","journal-title":"Eur. Biophys. J."},{"key":"763_CR88","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25115718","volume":"25","author":"G Guerrini","year":"2024","unstructured":"Guerrini, G., Mehn, D., Scaccabarozzi, D., Gioria, S. & Calzolai, L. Analytical ultracentrifugation to assess the quality of LNP-mRNA therapeutics. Int. J. Mol. Sci. 25, 5718 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"763_CR89","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2022.08.009","volume":"350","author":"B Bogaert","year":"2022","unstructured":"Bogaert, B. et al. A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs. J. Control. Rel. 350, 256\u2013270 (2022).","journal-title":"J. Control. Rel."},{"key":"763_CR90","volume":"8","author":"M Kim","year":"2023","unstructured":"Kim, M. et al. Novel piperazine-based ionizable lipid nanoparticles allow the repeated dose of mRNA to fibrotic lungs with improved potency and safety. Bioeng. Transl. Med. 8, e10556 (2023).","journal-title":"Bioeng. Transl. Med."},{"key":"763_CR91","unstructured":"Peer, D. & Ramishetti, S. Cationic lipids for nucleic acid delivery and preparation thereof. European patent EP3538515A1 (2018)."},{"key":"763_CR92","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1021\/acs.molpharmaceut.3c00956","volume":"20","author":"A-G Reinhart","year":"2023","unstructured":"Reinhart, A.-G. et al. Investigations into mRNA lipid nanoparticles shelf-life stability under nonfrozen conditions. Mol. Pharm. 20, 6492\u20136503 (2023).","journal-title":"Mol. Pharm."},{"key":"763_CR93","volume":"27","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery in vivo. iScience 27, 109804 (2024).","journal-title":"iScience"},{"key":"763_CR94","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jconrel.2024.07.046","volume":"373","author":"JB Simonsen","year":"2024","unstructured":"Simonsen, J. B. A perspective on bleb and empty LNP structures. J. Control. Rel. 373, 952\u2013961 (2024).","journal-title":"J. Control. Rel."},{"key":"763_CR95","volume":"35","author":"MHY Cheng","year":"2023","unstructured":"Cheng, M. H. Y. et al. Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency. Adv. Mater. 35, 2303370 (2023).","journal-title":"Adv. Mater."},{"key":"763_CR96","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1039\/C8OB00734A","volume":"16","author":"S Shishodia","year":"2018","unstructured":"Shishodia, S. et al. NMR analyses on N-hydroxymethylated nucleobases \u2014 implications for formaldehyde toxicity and nucleic acid demethylases. Org. Biomol. Chem. 16, 4021\u20134032 (2018).","journal-title":"Org. Biomol. Chem."},{"key":"763_CR97","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","volume":"27","author":"RC Cioc","year":"2023","unstructured":"Cioc, R. C., Joyce, C., Mayr, M. & Bream, R. N. Formation of N-nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies. Org. Process Res. Dev. 27, 1736\u20131750 (2023).","journal-title":"Org. Process Res. Dev."},{"key":"763_CR98","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1021\/acs.oprd.3c00073","volume":"27","author":"IW Ashworth","year":"2023","unstructured":"Ashworth, I. W. et al. A consideration of the extent that tertiary amines can form N-nitroso dialkylamines in pharmaceutical products. Org. Process Res. Dev. 27, 1714\u20131718 (2023).","journal-title":"Org. Process Res. Dev."},{"key":"763_CR99","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1021\/acs.joc.0c02774","volume":"86","author":"JC Beard","year":"2021","unstructured":"Beard, J. C. & Swager, T. M. An organic chemist\u2019s guide to N-nitrosamines: their structure, reactivity, and role as contaminants. J. Org. Chem. 86, 2037\u20132057 (2021).","journal-title":"J. Org. Chem."},{"key":"763_CR100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2021.128962","volume":"416","author":"A Chaudhuri","year":"2021","unstructured":"Chaudhuri, A. et al. Kinetics and intensification of tertiary amine N-oxidation: towards a solventless, continuous and sustainable process. Chem. Eng. J. 416, 128962 (2021).","journal-title":"Chem. Eng. J."},{"key":"763_CR101","first-page":"22","volume":"37","author":"CA Challener","year":"2024","unstructured":"Challener, C. A. Increasing mRNA product stability with lyophilization. Biopharm. Int. 37, 22\u201325 (2024).","journal-title":"Biopharm. Int."},{"key":"763_CR102","volume":"8","author":"M Li","year":"2023","unstructured":"Li, M. et al. Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine. NPJ Vaccines 8, 153 (2023).","journal-title":"NPJ Vaccines"},{"key":"763_CR103","volume":"9","author":"L Ai","year":"2023","unstructured":"Ai, L. et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 9, 9 (2023).","journal-title":"Cell Discov."},{"key":"763_CR104","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao, H. et al. Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates. Signal Transduct. Target. Ther. 6, 438 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"763_CR105","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/acs.oprd.2c00330","volume":"27","author":"CJ Borths","year":"2023","unstructured":"Borths, C. J. et al. Nitrosamine risk assessments in oligonucleotides. Org. Process Res. Dev. 27, 1693\u20131702 (2023).","journal-title":"Org. Process Res. Dev."},{"key":"763_CR106","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","volume":"112","author":"E Oude Blenke","year":"2023","unstructured":"Oude Blenke, E. et al. The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case. J. Pharm. Sci. 112, 386\u2013403 (2023).","journal-title":"J. Pharm. Sci."},{"key":"763_CR107","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2023.03.039","volume":"357","author":"S Meulewaeter","year":"2023","unstructured":"Meulewaeter, S. et al. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures. J. Control. Rel. 357, 149\u2013160 (2023).","journal-title":"J. Control. Rel."},{"key":"763_CR108","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1021\/acs.molpharmaceut.2c00587","volume":"19","author":"MI Henderson","year":"2022","unstructured":"Henderson, M. I., Eygeris, Y., Jozic, A., Herrera, M. & Sahay, G. Leveraging biological buffers for efficient messenger RNA delivery via lipid nanoparticles. Mol. Pharm. 19, 4275\u20134285 (2022).","journal-title":"Mol. Pharm."},{"key":"763_CR109","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3390\/pr10112428","volume":"10","author":"M Hom\u0161ak","year":"2022","unstructured":"Hom\u0161ak, M. et al. Assessment of a diverse array of nitrite scavengers in solution and solid state: a study of inhibitory effect on the formation of alkyl-aryl and dialkyl N-nitrosamine derivatives. Processes 10, 2428 (2022).","journal-title":"Processes"},{"key":"763_CR110","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.xphs.2023.03.022","volume":"112","author":"A-CV Bayne","year":"2023","unstructured":"Bayne, A.-C. V. et al. N-Nitrosamine mitigation with nitrite scavengers in oral pharmaceutical drug products. J. Pharm. Sci. 112, 1794\u20131800 (2023).","journal-title":"J. Pharm. Sci."},{"key":"763_CR111","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1021\/acsnano.2c10501","volume":"17","author":"H Tanaka","year":"2023","unstructured":"Tanaka, H. et al. Ready-to-use-type lyophilized lipid nanoparticle formulation for the postencapsulation of messenger RNA. ACS Nano 17, 2588\u20132601 (2023).","journal-title":"ACS Nano"},{"key":"763_CR112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).","journal-title":"Int. J. Pharm."},{"key":"763_CR113","doi-asserted-by":"crossref","first-page":"10634","DOI":"10.1021\/acsanm.0c01834","volume":"3","author":"SS Nogueira","year":"2020","unstructured":"Nogueira, S. S. et al. Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery. ACS Appl. Nano Mater. 3, 10634\u201310645 (2020).","journal-title":"ACS Appl. Nano Mater."},{"key":"763_CR114","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/pol.20230916","volume":"62","author":"Z Zhang","year":"2024","unstructured":"Zhang, Z., Sun, H., Giannino, J., Wu, Y. & Cheng, C. Biodegradable zwitterionic polymers as PEG alternatives for drug delivery. J. Polym. Sci. 62, 2231\u20132250 (2024).","journal-title":"J. Polym. Sci."},{"key":"763_CR115","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1093\/nar\/gkab764","volume":"49","author":"HK Wayment-Steele","year":"2021","unstructured":"Wayment-Steele, H. K. et al. Theoretical basis for stabilizing messenger RNA through secondary structure design. Nucleic Acids Res. 49, 10604\u201310617 (2021).","journal-title":"Nucleic Acids Res."},{"key":"763_CR116","volume":"15","author":"F Cheng","year":"2023","unstructured":"Cheng, F. et al. Research advances on the stability of mRNA vaccines. Viruses 15, 668 (2023).","journal-title":"Viruses"},{"key":"763_CR117","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1248\/cpb.c23-00550","volume":"72","author":"G Tsuji","year":"2024","unstructured":"Tsuji, G. et al. In silico prediction of N-nitrosamine formation pathways of pharmaceutical products. Chem. Pharm. Bull. 72, 166\u2013172 (2024).","journal-title":"Chem. Pharm. Bull."},{"key":"763_CR118","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","volume":"27","author":"R Nudelman","year":"2023","unstructured":"Nudelman, R. et al. The nitrosamine \u201csaga\u201d: lessons learned from five years of scrutiny. Org. Process Res. Dev. 27, 1719\u20131735 (2023).","journal-title":"Org. Process Res. Dev."}],"container-title":["Nature Reviews Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41570-025-00763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41570-025-00763-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41570-025-00763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:04:13Z","timestamp":1762347853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41570-025-00763-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":118,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1038\/s41570-025-00763-x","relation":{},"ISSN":["2397-3358"],"issn-type":[{"value":"2397-3358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"8 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.P. receives licensing fees (to patents of which he was an inventor) from, is invested in, consults (or sits on scientific advisory boards or boards of directors) or Founder and hold shares or conducts sponsored research at Tel Aviv University for the following entities: ART Biosciences, BioNTech SE, Earli Inc., Kernal Biologics Inc., LAND Medicine Inc., Merck KGaA, Newphase Ltd., NeoVac Ltd., RiboX Therapeutics, Roche, SirTLabs Corporation, and Teva Pharmaceuticals Inc. T.K. and A.\u0160. are employees of Sartorius BIA Separations d.o.o. A.\u0160. hold shares in Sartorius Stedim Biotech and Mediainvest. H.H. is an employee of NeoVac Ltd. and holds shares in the company. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}